SENTINEL U ADVANCED PRACTICE SERIES - CARDIOLOGY
SIMULATION: JOSEPH HOFFMAN | HEART FAILURE &
UNCONTROLLED HYPERTENSION | FULL CASE, CLINICAL
REASONING, DIAGNOSTICS & COMPLETE CARE PLAN | 2026
UPDATED
143 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
SENTINEL U ADVANCED PRACTICE SERIES - CARDIOLOGY SIMULATION: JOSEPH HOFFMAN | HEART
FAILURE & UNCONTROLLED HYPERTENSION | FULL CASE, CLINICAL REASONING, DIAGNOSTICS &
COMPLETE CARE PLAN | 2026 UPDATED. It contains 143 carefully selected questions that reflect the most
current exam content and testing strategies. Each question is accompanied by a correct answer and a detailed
rationale that explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 143 Questions
Foundations - Application - Sentinel U Advanced Series Cardiology Simulation Joseph Hoffman Heart
Failure & Uncontrolled Hypertension FULL CASE Clinical Reasoning Diagnostics & Complete CARE PLAN
2026 Updated Cardiology Heart Failure AND Uncontrolled Hypertension Management Graduate Msn/dnp
Advanced Nursing
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Heart Failure Classification 1-24 Heart Failure, Hypertension, Ejection Fraction, Finding,
Etiology AND Prescribed
Pathophysiology
Uncontrolled Hypertension 25-48 Heart Failure, Hypertension, Ejection Fraction, Finding, Hfref
Assessment RISK Factors
AND Management
Comprehensive 49-72 Heart Failure, Hypertension, Uncontrolled, Prescribed, Hfref
Cardiovascular Assessment
AND Clinical Reasoning
Diagnostic Testing AND 73-96 Heart Failure, Hypertension, Prescribed, Finding, Appropriate
Interpretation LABS ECG
Echocardiography AND
Imaging
Pharmacological 97-120 Failure, Heart, Hypertension, Finding, Acute
Management OF Heart
Failure AND Hypertension
Non-pharmacological AND 121-143 Heart Failure, Hypertension, Prescribed, Ejection Fraction,
Lifestyle Interventions FOR Finding
Cardiovascular Disease
TOTAL 143 All questions include answers and detailed rationales
,Section A - Heart Failure Classification Etiology AND
Pathophysiology
Q1.
Which of the following best reflects the 2026 guideline-directed medical therapy for a
patient with heart failure with reduced ejection fraction (HFrEF) and NYHA class II
symptoms?
A. ACE inhibitor, beta-blocker, and diuretic B. Sacubitril/valsartan, beta-blocker, MRA,
as needed and SGLT2 inhibitor
C. Beta-blocker, calcium channel blocker, D. Hydralazine/isosorbide dinitrate and a
and loop diuretic diuretic
Correct: B - Sacubitril/valsartan, beta-blocker, MRA, and SGLT2 inhibitor
Rationale:Current guidelines recommend quadruple therapy for HFrEF: ARNI (or ACEi/ARB),
evidence-based beta-blocker, MRA, and SGLT2 inhibitor to reduce mortality and
hospitalizations. Option A is incomplete, C includes a contraindicated non-dihydropyridine
CCB, and D is reserved for specific populations.
Why the other answers are wrong:
A. Lacks MRA and SGLT2 inhibitor, which are core components of guideline-directed therapy.
C. Non-dihydropyridine calcium channel blockers are generally contraindicated in HFrEF due to
negative inotropic effects.
D. Hydralazine/isosorbide dinitrate is primarily for patients who cannot tolerate
ACEi/ARB/ARNI, not first-line for all.
Reference: 2026 ACC/AHA/HFSA Guideline for the Management of Heart Failure, Section 7.3
Q2.
A patient with acute decompensated heart failure presents with dyspnea, orthopnea, and
jugular venous distension. Which diagnostic finding would most strongly support a
diagnosis of heart failure with preserved ejection fraction (HFpEF)?
A. Left ventricular ejection fraction of 35% B. Elevated BNP and echocardiographic
evidence of diastolic dysfunction
C. S3 gallop and elevated troponin D. Reduced cardiac output with increased
systemic vascular resistance
Correct: B - Elevated BNP and echocardiographic evidence of diastolic dysfunction
Page 3
, Section A - Heart Failure Classification Etiology AND Pathophysiology
Rationale: HFpEF is characterized by elevated filling pressures and diastolic dysfunction
despite a normal ejection fraction (typically 50%). Elevated BNP supports heart failure, and
diastolic dysfunction on echo is key. Option A indicates HFrEF, C suggests acute coronary
syndrome or HFrEF, and D is nonspecific.
Why the other answers are wrong:
A. EF of 35% indicates HFrEF, not HFpEF.
C. S3 gallop is more common in HFrEF; troponin elevation suggests ischemia.
D. This hemodynamic pattern is seen in cardiogenic shock or HFrEF, not specific to HFpEF.
Reference: 2026 ACC/AHA/HFSA Guideline, Section 4.2
Q3.
Which social determinant of health most directly impacts medication adherence in a
patient with heart failure and uncontrolled hypertension?
A. Health literacy level B. Access to transportation
C. Cost of medications D. Social support network
Correct: C - Cost of medications
Rationale:Medication cost is a leading barrier to adherence, especially for brand-name
ARNIs and SGLT2 inhibitors. While health literacy, transportation, and social support also
affect adherence, cost is the most direct financial deterrent. Screening for cost-related
nonadherence is recommended.
Why the other answers are wrong:
A. Health literacy affects understanding but not necessarily the ability to afford medications.
B. Transportation affects access to care but not directly the ability to pay for prescriptions.
D. Social support can help with reminders but does not overcome financial barriers.
Reference: Magnani et al. (2024). Social Determinants of Health and Cardiovascular Disease. JACC,
83(4), 456-470.
Q4.
A patient with heart failure and hypertension is prescribed spironolactone. Which
laboratory value requires immediate follow-up?
A. Potassium 5.8 mEq/L B. Sodium 134 mEq/L
C. Creatinine 1.2 mg/dL D. Hemoglobin 11.5 g/dL
Correct: A - Potassium 5.8 mEq/L
Rationale:Spironolactone, a potassium-sparing diuretic, can cause hyperkalemia. A
potassium level of 5.8 mEq/L is dangerously high and requires immediate intervention. The
other values are either within normal limits or not directly life-threatening.
Page 4
SIMULATION: JOSEPH HOFFMAN | HEART FAILURE &
UNCONTROLLED HYPERTENSION | FULL CASE, CLINICAL
REASONING, DIAGNOSTICS & COMPLETE CARE PLAN | 2026
UPDATED
143 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
SENTINEL U ADVANCED PRACTICE SERIES - CARDIOLOGY SIMULATION: JOSEPH HOFFMAN | HEART
FAILURE & UNCONTROLLED HYPERTENSION | FULL CASE, CLINICAL REASONING, DIAGNOSTICS &
COMPLETE CARE PLAN | 2026 UPDATED. It contains 143 carefully selected questions that reflect the most
current exam content and testing strategies. Each question is accompanied by a correct answer and a detailed
rationale that explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 143 Questions
Foundations - Application - Sentinel U Advanced Series Cardiology Simulation Joseph Hoffman Heart
Failure & Uncontrolled Hypertension FULL CASE Clinical Reasoning Diagnostics & Complete CARE PLAN
2026 Updated Cardiology Heart Failure AND Uncontrolled Hypertension Management Graduate Msn/dnp
Advanced Nursing
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Heart Failure Classification 1-24 Heart Failure, Hypertension, Ejection Fraction, Finding,
Etiology AND Prescribed
Pathophysiology
Uncontrolled Hypertension 25-48 Heart Failure, Hypertension, Ejection Fraction, Finding, Hfref
Assessment RISK Factors
AND Management
Comprehensive 49-72 Heart Failure, Hypertension, Uncontrolled, Prescribed, Hfref
Cardiovascular Assessment
AND Clinical Reasoning
Diagnostic Testing AND 73-96 Heart Failure, Hypertension, Prescribed, Finding, Appropriate
Interpretation LABS ECG
Echocardiography AND
Imaging
Pharmacological 97-120 Failure, Heart, Hypertension, Finding, Acute
Management OF Heart
Failure AND Hypertension
Non-pharmacological AND 121-143 Heart Failure, Hypertension, Prescribed, Ejection Fraction,
Lifestyle Interventions FOR Finding
Cardiovascular Disease
TOTAL 143 All questions include answers and detailed rationales
,Section A - Heart Failure Classification Etiology AND
Pathophysiology
Q1.
Which of the following best reflects the 2026 guideline-directed medical therapy for a
patient with heart failure with reduced ejection fraction (HFrEF) and NYHA class II
symptoms?
A. ACE inhibitor, beta-blocker, and diuretic B. Sacubitril/valsartan, beta-blocker, MRA,
as needed and SGLT2 inhibitor
C. Beta-blocker, calcium channel blocker, D. Hydralazine/isosorbide dinitrate and a
and loop diuretic diuretic
Correct: B - Sacubitril/valsartan, beta-blocker, MRA, and SGLT2 inhibitor
Rationale:Current guidelines recommend quadruple therapy for HFrEF: ARNI (or ACEi/ARB),
evidence-based beta-blocker, MRA, and SGLT2 inhibitor to reduce mortality and
hospitalizations. Option A is incomplete, C includes a contraindicated non-dihydropyridine
CCB, and D is reserved for specific populations.
Why the other answers are wrong:
A. Lacks MRA and SGLT2 inhibitor, which are core components of guideline-directed therapy.
C. Non-dihydropyridine calcium channel blockers are generally contraindicated in HFrEF due to
negative inotropic effects.
D. Hydralazine/isosorbide dinitrate is primarily for patients who cannot tolerate
ACEi/ARB/ARNI, not first-line for all.
Reference: 2026 ACC/AHA/HFSA Guideline for the Management of Heart Failure, Section 7.3
Q2.
A patient with acute decompensated heart failure presents with dyspnea, orthopnea, and
jugular venous distension. Which diagnostic finding would most strongly support a
diagnosis of heart failure with preserved ejection fraction (HFpEF)?
A. Left ventricular ejection fraction of 35% B. Elevated BNP and echocardiographic
evidence of diastolic dysfunction
C. S3 gallop and elevated troponin D. Reduced cardiac output with increased
systemic vascular resistance
Correct: B - Elevated BNP and echocardiographic evidence of diastolic dysfunction
Page 3
, Section A - Heart Failure Classification Etiology AND Pathophysiology
Rationale: HFpEF is characterized by elevated filling pressures and diastolic dysfunction
despite a normal ejection fraction (typically 50%). Elevated BNP supports heart failure, and
diastolic dysfunction on echo is key. Option A indicates HFrEF, C suggests acute coronary
syndrome or HFrEF, and D is nonspecific.
Why the other answers are wrong:
A. EF of 35% indicates HFrEF, not HFpEF.
C. S3 gallop is more common in HFrEF; troponin elevation suggests ischemia.
D. This hemodynamic pattern is seen in cardiogenic shock or HFrEF, not specific to HFpEF.
Reference: 2026 ACC/AHA/HFSA Guideline, Section 4.2
Q3.
Which social determinant of health most directly impacts medication adherence in a
patient with heart failure and uncontrolled hypertension?
A. Health literacy level B. Access to transportation
C. Cost of medications D. Social support network
Correct: C - Cost of medications
Rationale:Medication cost is a leading barrier to adherence, especially for brand-name
ARNIs and SGLT2 inhibitors. While health literacy, transportation, and social support also
affect adherence, cost is the most direct financial deterrent. Screening for cost-related
nonadherence is recommended.
Why the other answers are wrong:
A. Health literacy affects understanding but not necessarily the ability to afford medications.
B. Transportation affects access to care but not directly the ability to pay for prescriptions.
D. Social support can help with reminders but does not overcome financial barriers.
Reference: Magnani et al. (2024). Social Determinants of Health and Cardiovascular Disease. JACC,
83(4), 456-470.
Q4.
A patient with heart failure and hypertension is prescribed spironolactone. Which
laboratory value requires immediate follow-up?
A. Potassium 5.8 mEq/L B. Sodium 134 mEq/L
C. Creatinine 1.2 mg/dL D. Hemoglobin 11.5 g/dL
Correct: A - Potassium 5.8 mEq/L
Rationale:Spironolactone, a potassium-sparing diuretic, can cause hyperkalemia. A
potassium level of 5.8 mEq/L is dangerously high and requires immediate intervention. The
other values are either within normal limits or not directly life-threatening.
Page 4
